GB0139: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 41 patientsc19early.org

GB0139 for COVID-19

Serious outcome risk
GB0139
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−40%
Mortality (1)−40%
RCTs (1)−40%
Late (1)−40%
00.511.5+
← GB0139
reduces riskIncreased
risk →
c19early.org
October 2026

GB0139 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.49death4/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →
c19early.org
October 2026

GB0139 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.494/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →
c19early.org
October 2026

GB0139 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.49death4/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →
c19early.org
October 2026

GB0139 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.49death4/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →
c19early.org
October 2026

GB0139 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.494/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →
c19early.org
October 2026

GB0139 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gaughan (RCT)−40%1.40 · 0.36–5.49death4/203/21DEFINE
Late treatment−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−40%1.40 · 0.36–5.494/203/2140% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← GB0139
reduces riskGB0139
increases risk →